An increasing interest in zirconium-89 ( 89 Zr) for preclinical and clinical immunopositron emission tomography (PET) is owed to its favourable decay characteristics (t 1/2 = 78.4 h, β + = 22.8%, E β+max = 901 keV) for the radiolabelling of antibodies which have long biological half-lives.
Zr) for preclinical and clinical immunopositron emission tomography (PET) is owed to its favourable decay characteristics (t 1/2 = 78.4 h, β + = 22.8%, E β+max = 901 keV) for the radiolabelling of antibodies which have long biological half-lives. [1] [2] [3] [4] Currently, deferoxamine (DFO) is the chelator most commonly used to radiolabel biomolecules with 89 Zr. 5 DFT modelling showed that the coordination sphere in the Zr-DFO complex consists of the Zr 4+ cation, six donor atoms belonging to the DFO molecule, and other two coordination sites being occupied by water molecules. 6, 7 As a result of this incomplete coordination of 89 Zr by the hexadentate DFO molecule, the 89 Zr-DFO complex undergoes a certain degree of demetallation in vivo with the released 89 Zr taken up by the bone. 8 This is of concern because bone uptake of free 89 Zr 4+ is undesirable owing to the high radiation dose to bone marrow; furthermore this background uptake can confound image acquisition of bone malignancies such as bone metastases. To solve the instability, different strategies have been investigated. Alternative hexadentate macrocycles (i.e Fusarinine C) and hydroxypyridinone-based compounds (i.e. CP256) have been produced and tested but showed either no improvement or poorer stability in vivo when compared to DFO. 9, 10 Additionally, a variety of either linear or macrocyclic octadentate chelators have been developed with structures hinged around hydroxamic acid or hydroxypyridinone moieties which resulted in 89 Zr-complexes displaying either increased or decreased stability compared to DFO. [11] [12] [13] [14] [15] [16] White et al. described the use of a DFO-1-hydroxy-2-pyridone ligand (DFO-HOPO) as an effective sequestering agent for the treatment of plutonium (IV) intoxication (Fig. 1) . 17 The authors showed that the addition of one 1,2-HOPO molecule to DFO produced a low toxicity octadentate chelator which yielded very stable complexes with Pu(IV) at physiological pH. Herein, we report an updated synthesis of DFO-HOPO (3) which was then evaluated as an octahedral ligand for 89 Zr. The stability of the radiocomplex was tested in vitro and in vivo and compared to 89 Zr-DFO in order to confirm 3 as a viable alternative to the chelators for 89 Zr already described in the literature.
The synthesis of DFO-HOPO (3) was adapted from a literature procedure. 17 In brief, commercially available DFO was reacted with hydroxamic acid chloride (2) and the product (3) was isolated by semi-preparative RP-HPLC (Scheme S1). No protection of the N-hydroxyl group of 1 was necessary. To determine and characterise the coordination capabilities of the chelator, the non-radioactive nat Zr complex of DFO-HOPO ( nat Zr-3) was prepared in macroscopic scale by mixing the chelator with ZrCl 4 at room temperature. Showing the value of 784.247 m/z, the high resolution mass spectrometry (HRMS) analysis of nat Zr-3 confirmed the expected complex mass to indicate a metal-to-ligand binding ratio of 1:1. Examination by RP-HPLC showed the elution of nat Zr-3 as a single peak at 7:20 min:sec, ca 33 seconds before HOPO-DFO (3). The coordination of the metal ion by the chelator was further confirmed by infrared spectrometry (IR) analysis which showed a red-shift in the main carbonyl stretching band from ca 1620 to ca 1600 cm -1 . Additional characterisation of the complex by ultraviolet-visible spectroscopy (UV-Vis) showed no detectable difference between the absorption spectra of nat Zr-3 and 3. Moreover, NMR analysis of the nat Zr complex could not be performed due to its poor solubility in any solvent.
To verify the steric and electronic ability of 3 to form a Zr(IV) octadentate chelate, density functional theory (DFT) calculations were carried out. The optimised geometry (based on the lower energy conformation) shows the metal centre coordinated to eight oxygen atoms of the chelator (Fig. 2) . The Zr-O bond distances were in the range of 2.14 -2.36 Å, in agreement with values reported in the literature for similar complexes. 11, 12 In common with 89 Zr-DFO, the preparation of 89 Zr-3 was performed as previously described in the literature by incubating the chelator with a neutralised 89 Zr solution at room temperature for 1 h (pH 7) to guarantee a quantitative (>99%) radiolabelling which could be achieved up to 20 MBq/nmol even at low concentration of the chelators (3-8 µM). 18 All reactions were monitored by radioactive instant thin layer chromatography (radio-ITLC). A variety of mobile and stationary phases were tested to find the optimum analytical conditions for both 89 Zr-3 and 89 Zr-DFO, which was used as a comparison. The elution profiles of both the radioactive complexes were affected by the type of stationary phase employed, and only the positively charged 89 Zr-DFO (consequence of the hexadentate chelation of 89 Zr) was influenced also by the mobile phase pH, when SG-ITLC strips were used. The results suggest that, differently from 89 Zr-DFO, 89 Zr-3 is present in solution as a neutral complex, achievable through the octadentate chelation of 89 Zr. This finding further advocates the involvement of the 1,2-HOPO moeity of 3 in the coordination of the metal centre. Enabling the elution of 89 Zr-3 and the 89 Zr-DFO as well defined and separated bands (R f of 0.6 and 0.1 respectively on SG-ITLC strips), ammonium acetate (0.1 M, pH 7) was used as mobile phase for the ITLC analysis. Interestingly, the radio-ITLC of 89 Zr-3 revealed the presence of two well-separated spots (R f of ca 0.6 and 0.1); the relative intensity of the spots was dependent on the specific activity of the product (i.e. concentration of the chelator) and on time. By lowering the specific activities of the product, with a consequent increase of the concentration of 3, a decrease of the band having R f = 0.1 was observed. After 24 hours at ambient temperature, only the band having R f = 0.6 was detected. Performing the radiolabelling reaction at 80°C reduced the quantity of the product eluting with an R f = 0.1 but did not prevent it from forming. These observations suggest that the two bands represent two different forms of the 89 Zr-3 complex; an initial transitional kinetic product which converted into a final thermodynamically stable product. Examination of the chromatographic data of 89 Zr-3 could help explain the phenomenon; the transitional product was detected at the origin of the radio-ITLC strip (R f = 0.1 at pH 7) suggesting it was charged (similarly to hexacoordinated 89 Zr-DFO), possibly as the result of incomplete coordination of the radiometal. With an R f = 0.6 (at pH 7), the thermodynamically stable final product was most likely neutral, a condition which would be achieved by the complete chelation of 89 Zr by octadentate 3. Moreover, radio-HPLC analysis of 89 Zr-3 after 24 hours showed only one product (corresponding to the band with R f = 0.6 on radio-ITLC) having an elution profile very similar to that of nat Zr-3 suggesting a similar identity as an octadentate complex. Importantly, no 89 Zr was released during the transition.
The stability of 89 Zr-3 was initially assessed by a simple radio-ITLC analysis using an acidic buffer (pH 2) as mobile phase. Differently from 89 Zr-DFO (14.4 ± 4.65% radioactivity not associated with DFO), 89 Zr-3 showed no demetallation as a result of the enhanced coordination of the metal centre by the octadentate ligand. To mimic what might happen in vivo, a challenge assay assessed the stability of 89 Zr-3 to transchelation in the presence of a large excess of either EDTA or DFO (pH 7). In both challenges, 89 Zr-3 showed no transchelation with >99% intact complex after 7 days (Table 1) . By comparison, 89 Zr-DFO demonstrated transchelation toward EDTA with 65.5 % of intact complex after 7 days (Table 1) . Moreover, a complete transmetallation of 89 Zr-DFO towards 3 was achieved in a matter of hours. Further experiments aiming to test the inertness of 89 Zr-3 were performed in mouse serum. With >99 % intact complex after incubation at 37°C for 7 days, 89 Zr-3 showed a higher stability compared to 89 Zr-DFO (90.6% intact complex) ( Table  1) .
PET imaging and comparative biodistribution studies were performed in healthy mice for 89 Zr-3 and 89 Zr-DFO. At 1 h p.i. of 89 Zr-3, the radioactivity was observed mainly in the bladder and intestine; some activity was also visible in the gall bladder. At 4 and 24 h p.i., most of the residual radioactivity was in the gut. These observations indicate a rapid renal clearance together with a certain extent of a slower hepatobiliary excretion. The hydrophilicity of the complexes is an important physiochemical property which regulates their distribution, metabolism, and elimination in vivo. The LogD 7.4 of neutral complex 89 Zr-3 was found to be -0.87 ± 0.03 which indicates a less hydrophilic character than the positively charged 89 Zr-DFO (-3.0 ± 0.01) and can explain the clearance pathway. 9 After 24 h, the radioactivity level was minimal therefore no additional imaging studies at longer time points were carried out. Importantly, no uptake of 89 Zr in the bone was observed at any time point (Fig. 3) .
Corroborating the PET images, the biodistribution studies clearly showed the participation of both the renal and hepatobiliary systems in the clearance of 89 Zr-3 (Fig. 4) . Most of the radioactivity had already cleared through the kidneys at 1 h p.i. (1.39 ± 0.1%ID/g), while at 4h p.i. the residual activity was localised in the gut (mostly small intestine with 0.898 ± 0.252% ID/g). Differently from 89 Zr-DFO (0.93 ± 0.11%ID/g still present in the kidneys), 89 Zr-3 was almost completely cleared from the body at 24 h p.i. Although the values are quite low, 89 Zr-DFO showed ca 10-fold higher activity accumulation in the bone than 89 Zr-3 at 24 h p.i (0.037 ± 0.002 and 0.004 ± 0.001 for 89 Zr-DFO and 89 Zr-3 respectively). This phenomenon could be correlated to either the higher level of radioactivity still present in the animals injected with 89 Zr-DFO or to an improved in vivo stability of 89 Zr-3 compared to 89 Zr-DFO.
In summary, the 89 Zr-3 complex exhibited improved stability compared to 89 Zr-DFO in both challenge assays and in serum; the capability and favourability of 3 to form a stable chelate was clearly demonstrated by the complete transchelation of 89 Zr from 89 Zr-DFO in ca 3 h. The in vivo studies showed that 89 Zr-3 cleared the body via the renal and hepatobiliary systems. However, once conjugated to a biomolecule the pharmacokinetics of the final radioconjugate will depend mainly on the biomolecule itself. Importantly, the straightforward synthesis of 3 from the commercially available DFO is amenable to allow the synthesis of a bifunctional chelator which is currently underway in our laboratory. The promising DFO-HOPO molecule is a valuable addition to the selection of available chelators for 89 Zr in search of successful successors of DFO for clinical immuno-PET applications based on important characteristics such as synthesis, chelate stability and in vivo pharmacokinetics. 
